Scientist II/Senior Scientist I, DMPK

Zealand Pharma U.S., Inc.; Cambridge (MA); On-site; USD 90,000 - 130,000; Full time

Job summary

Zealand Pharma U.S., Inc. in Cambridge, MA is expanding its Global DMPK group and seeks a scientist with hands-on LC-MS bioanalysis and DMPK expertise to advance complex molecule modalities.

The role covers method development, PK study design, and data interpretation, with emphasis on bioanalysis of peptides, antibodies, and conjugates, and collaboration across Discovery, Translational, and Regulatory teams.

Qualifications

• PhD in pharmaceutical sciences, biochemistry, analytical chemistry, chemistry or a related scientific field with 0-3 years of relevant industry or postdoctoral experience.
• M.S. with approximately 3-6 years of relevant industry experience.
• B.S./B.A. with approximately 5-8+ years of relevant industry experience.
• Solid hands-on background in LC-MS bioanalysis and assay development.
• Experience in PK study design, data interpretation, and translating DMPK insights into actionable project recommendations is an advantage.
• Experience with bioanalysis of complex molecules such as peptides, antibodies and conjugates is an advantage.
• Familiarity with ADME assays and metabolite ID for larger molecules, as well as experience with digital/automation-enabled bioanalysis and DMPK workflows, is an advantage.

Responsibilities

• Contribute to the development of DMPK discovery platforms and bioanalysis capabilities for complex drug modalities (e.g., antibodies, antibody‑peptide conjugates and peptides).
• Execute the LC-MS bioanalysis workflow, from input to PK study design to method development, sample analysis and reporting of PK and exposure data.
• Support PK and metabolite identification across discovery projects.
• Design and conduct in‑vitro assays, such as metabolic stability experiments or other project‑relevant DMPK assays.
• Contribute to continuous improvement by adopting efficient, digital and automation‑enabled approaches within DMPK workflows.

Skills

LC-MS bioanalysis

DMPK knowledge

Analytical chemistry

Bioanalysis of complex molecules

Education

PhD in pharmaceutical sciences / biochemistry / analytical chemistry

MS with 3–6 years experience

BS/BA with 5–8+ years experience

Tools

LC-MS instrumentation

Bioanalysis software

Job description

Does it excite you to optimize DMPK properties, and do you have hands‑on experience with LC-MS bioanalysis of complex molecular formats? If this sounds like you, and you are ready to take on a broad area of responsibilities, then you could be our new colleague. Your new position Zealand Pharma is significantly expanding its global R&D capabilities and establishing new research units in Cambridge, MA to advance diverse drug modality capabilities in metabolic disease. As part of this expansion, you will play a central role in the DMPK group, advancing LC-MS capabilities and DMPK science within complex molecular formats. This is a unique opportunity for a scientist with strong scientific curiosity and technical expertise across mass spectrometry, pharmacokinetics, drug metabolism and bioanalysis.

Key Responsibilities

• Contribute to the development of DMPK discovery platforms and bioanalysis capabilities for complex drug modalities (e.g., antibodies, antibody‑peptide conjugates and peptides).
• Execute the LC-MS bioanalysis workflow, from input to PK study design to method development, sample analysis and reporting of PK and exposure data.
• Support PK and metabolite identification across discovery projects.
• Design and conduct in‑vitro assays, such as metabolic stability experiments or other project‑relevant DMPK assays.
• Contribute to continuous improvement by adopting efficient, digital and automation‑enabled approaches within DMPK workflows.

Your Profile

• PhD in pharmaceutical sciences, biochemistry, analytical chemistry, chemistry or a related scientific field with 0-3 years of relevant industry or postdoctoral experience.
• M.S. with approximately 3-6 years of relevant industry experience.
• B.S./B.A. with approximately 5-8+ years of relevant industry experience.
• Solid hands‑on background in LC-MS bioanalysis and assay development.
• Experience in PK study design, data interpretation, and translating DMPK insights into actionable project recommendations is an advantage.
• Experience with bioanalysis of complex molecules such as peptides, antibodies and conjugates is an advantage.
• Familiarity with ADME assays and metabolite ID for larger molecules, as well as experience with digital/automation‑enabled bioanalysis and DMPK workflows, is an advantage.

Your new team

You will join the Global DMPK department within Pharmacokinetics, Immunogenicity and Bioanalytical Sciences, working closely with cross‑functional R&D stakeholders (e.g., Discovery, Translational, Toxicology, Clinical Pharmacology and Regulatory) to shape study strategies, interpret data, and communicate DMPK risks and recommendations.

Let’s bond and be bold

We have a unique culture, characterized by excellent teamwork and strong engagement across the organization. And we want you to help us strengthen this culture. Making bonds is at the core of everything we do. From discovering and developing the best new peptide drugs for patients, to engaging with our partners or connecting with each other. We bond through curiosity and playfulness as a team, allowing ourselves to challenge common thinking and drive future innovation.

Join us and let’s bond and be bold.

Applications will be reviewed as they come in. While a cover letter is not required, please include a few sentences in your CV explaining your motivation for applying. We are committed to an inclusive recruitment process and welcome applications from all job applicants.

About Zealand Pharma A/S

Zealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on advancing medicines for obesity and metabolic health. Combining more than 25 years of peptide R&D expertise with a proprietary data platform that leverages advanced data‑driven and AI/ML approaches, Zealand Pharma aims to lead a new era in obesity and metabolic health. To date, more than ten Zealand Pharma‑invented drug candidates have entered clinical development, of which two products have reached the market and three candidates are in late‑stage development. The Company has collaborations with global pharmaceutical and biotechnology partners for research, development, and commercialization. Founded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with a U.S. presence in Cambridge, Massachusetts.

Learn more at www.zealandpharma.com. Since our founding in 1998, Zealand Pharma has built a core expertise in the discovery, design, and development of therapeutic peptides. This expertise has led to an R&D pipeline of innovative investigational candidates designed to address a broad range of disease areas. We have four therapeutic focus areas: obesity, rare diseases, chronic inflammation, and type 1 diabetes. In obesity, our peptide capabilities place us in a unique position to address a vast global health challenge and positively impact hundreds of millions of lives. Within rare diseases, we have a long‑standing commitment to deliver new treatments to patients living with congenital hyperinsulinism and short bowel syndrome. For chronic inflammatory diseases, we are progressing peptide programs focused on high‑profile targets shown to be difficult to address with small molecules and antibodies. For type 1 diabetes, we aspire to change the management of this disease. Our strategy is to pursue global co‑development and commercialization partnerships that complement and extend our capabilities across the value chain to deliver new peptide therapies to people who need them.